Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

Logo-Geneoscopy-400
11/19/2021

Geneoscopy Announces Positive Results of Colorectal Cancer Screening Test in Prospective, Multicenter Clinical Study

READ MORE
Logo-Geneoscopy-400
11/16/2021

Geneoscopy Closes $105M in Financing to Advance its Noninvasive Multifactor RNA Screening Test for Colorectal Cancer Prevention

READ MORE
wugen-logo-400
11/12/2021

Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

READ MORE
CareVet-Logo-New
11/12/2021

Clayton vet manager makes 100th acquisition, sees 'enormous' potential for more

READ MORE
CareVet-Logo-New
11/12/2021

Enhanced benefits program launched by national network

READ MORE
wugen-logo-400
11/10/2021

Wugen to Present Virtually at the Upcoming Jefferies London Healthcare Conference

READ MORE
C4-logo-400
11/10/2021

C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

READ MORE
wugen-logo-400
11/09/2021

Wugen Announces Data Presentation at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

READ MORE
CareVet-Logo-New
11/05/2021

Is your hospital ready for the future?

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300